Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Show other versions (1)
Bibliographic Details
Main Authors: Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus, Peter A. Kaufman
Format: Article
Language:English
Published: SAGE Publishing 2016-06-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:http://www.la-press.com/subgroup-analyses-from-a-phase-3-open-label-randomized-study-of-eribul-article-a5733
id doaj-18ec52c72d3d467988220da3c03c7aa2
record_format Article
spelling doaj-18ec52c72d3d467988220da3c03c7aa22020-11-25T03:17:51ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342016-06-0120161077845733Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast CancerChris TwelvesAhmad AwadaJavier CortesLouise YelleGalina VelikovaMartin S. OlivoJames SongCorina E. DutcusPeter A. Kaufmanhttp://www.la-press.com/subgroup-analyses-from-a-phase-3-open-label-randomized-study-of-eribul-article-a5733
collection DOAJ
language English
format Article
sources DOAJ
author Chris Twelves
Ahmad Awada
Javier Cortes
Louise Yelle
Galina Velikova
Martin S. Olivo
James Song
Corina E. Dutcus
Peter A. Kaufman
spellingShingle Chris Twelves
Ahmad Awada
Javier Cortes
Louise Yelle
Galina Velikova
Martin S. Olivo
James Song
Corina E. Dutcus
Peter A. Kaufman
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
Breast Cancer: Basic and Clinical Research
author_facet Chris Twelves
Ahmad Awada
Javier Cortes
Louise Yelle
Galina Velikova
Martin S. Olivo
James Song
Corina E. Dutcus
Peter A. Kaufman
author_sort Chris Twelves
title Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
title_short Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
title_full Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
title_fullStr Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
title_full_unstemmed Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
title_sort subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer
publisher SAGE Publishing
series Breast Cancer: Basic and Clinical Research
issn 1178-2234
publishDate 2016-06-01
url http://www.la-press.com/subgroup-analyses-from-a-phase-3-open-label-randomized-study-of-eribul-article-a5733
work_keys_str_mv AT christwelves subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT ahmadawada subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT javiercortes subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT louiseyelle subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT galinavelikova subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT martinsolivo subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT jamessong subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT corinaedutcus subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
AT peterakaufman subgroupanalysesfromaphase3openlabelrandomizedstudyoferibulinmesylateversuscapecitabineinpretreatedpatientswithadvancedormetastaticbreastcancer
_version_ 1724629523996082176

Similar Items